This page is sponsored by a grant from The Borman Family Foundation. Additional support provided by the Sam L. Cohen Foundation.
Dementia Care Training Programs
More than half of long-term care residents have some form of dementia. Specialized training will help you care for them and increase your productivity.
Eliminating the Barriers to Person-Centered Care in Your Facility
This 28-minute audio excerpt was recorded at the Alzheimer’s Association, Maine Chapter’s Annual Conference “Improving Care for People with Advanced Dementia” May 19th, 2009, Portland, Maine. It features Cherie Rosemond, Ph.D, GCS, PT discussing person-centered care and the challenges that your organization must navigate when implementing new programs.
Principles for a dignified diagnosis
Principles for a Dignified Diagnosis is the first statement of its kind written by people with dementia on the subject of the Alzheimer diagnostic experience. The 2008 report Voices of Alzheimer's Disease examined the rich dialogue at these town halls and identified diagnostic challenges and dissatisfying interactions with the medical community as two major challenges articulated by people living with the disease. The new, innovative Principles for a Dignified Diagnosis contains insights from people living with the disease on how to improve that experience.
Phase III interventional trials
Phase III clinical studies provide the chief evidence for safety and effectiveness that the U.S. Food and Drug Administration (FDA) considers in deciding whether to approve a drug. The following Alzheimer drugs in Phase III clinical studies are “interventional drugs” designed to slow or stop the progression of the disease.
Other types of interventional studies evaluate investigational medications that focus on treating symptoms or preventing the disease. Interventional studies are different from observational studies, in which researchers can only observe what happens to a group or groups of people undergoing a particular treatment and then record the outcomes.
Bapineuzumab is designed to bind to and remove the beta-amyloid peptide that accumulates in the brains of individuals with Alzheimer's. Bapineuzumab is given as a series of injections, delivering antibodies to beta-amyloid. This approach is called “passive immunization,” since the body is receiving the antibodies via the drug, rather than generating the antibodies itself. This drug is being tested in individuals with mild to moderate Alzheimer's. Approximately 4,000 subjects at more than 350 sites worldwide (include 200 sites in the United States and Canada) are expected to participate.